Manish A. Shah

Manish A. Shah, MD is Director of the Gastrointestinal Oncology Program and Professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital. He is a globally recognized leader in upper gastrointestinal oncology, with particular expertise in gastric, gastroesophageal junction (GEJ), and esophageal cancers. Dr. Shah was a principal investigator for the KEYNOTE-590 trial, which established pembrolizumab plus chemotherapy as a standard first-line regimen for advanced esophageal squamous cell carcinoma and adenocarcinoma, demonstrating survival benefit across PD-L1-selected populations. He has contributed extensively to understanding the molecular biology and heterogeneity of gastric cancer, including investigations of HER2 amplification, VEGFR signaling, and claudin 18.2 as emerging targets. Dr. Shah has served on multiple ASCO and NCCN guideline panels for esophageal and gastric cancers and has published more than 200 peer-reviewed papers. He is a past chair of the ASCO Upper GI Cancers Symposium and a key figure in translating biomarker-driven approaches into gastric and esophageal cancer clinical practice.